JP2011522874A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011522874A5 JP2011522874A5 JP2011513069A JP2011513069A JP2011522874A5 JP 2011522874 A5 JP2011522874 A5 JP 2011522874A5 JP 2011513069 A JP2011513069 A JP 2011513069A JP 2011513069 A JP2011513069 A JP 2011513069A JP 2011522874 A5 JP2011522874 A5 JP 2011522874A5
- Authority
- JP
- Japan
- Prior art keywords
- influenza
- virus
- virus strain
- vaccine
- container
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13191808P | 2008-06-12 | 2008-06-12 | |
| US61/131,918 | 2008-06-12 | ||
| GB0905570.8 | 2009-03-31 | ||
| GBGB0905570.8A GB0905570D0 (en) | 2009-03-31 | 2009-03-31 | Combined vaccines |
| PCT/IB2009/006038 WO2009150532A1 (en) | 2008-06-12 | 2009-06-12 | Combined influenza vaccines for seasonal and pandemic protection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011522874A JP2011522874A (ja) | 2011-08-04 |
| JP2011522874A5 true JP2011522874A5 (enExample) | 2012-07-19 |
Family
ID=40672059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011513069A Pending JP2011522874A (ja) | 2008-06-12 | 2009-06-12 | 季節性および汎流行性の防御のための混合インフルエンザワクチン |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20110200635A1 (enExample) |
| EP (1) | EP2303321A1 (enExample) |
| JP (1) | JP2011522874A (enExample) |
| KR (1) | KR20110019417A (enExample) |
| CN (1) | CN102245203A (enExample) |
| AU (1) | AU2009259006A1 (enExample) |
| CA (1) | CA2727322A1 (enExample) |
| GB (1) | GB0905570D0 (enExample) |
| WO (1) | WO2009150532A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2614802T3 (es) * | 2008-11-28 | 2017-06-02 | Statens Serum Institut | Vacunas contra la gripe optimizadas |
| AU2015203072B2 (en) * | 2009-02-10 | 2017-05-25 | Seqirus UK Limited | Influenza vaccine regimens for pandemic-associated strains |
| WO2010092476A1 (en) | 2009-02-10 | 2010-08-19 | Novartis Ag | Influenza vaccine regimens for pandemic-associated strains |
| CA2787099A1 (en) | 2009-03-30 | 2010-10-14 | Anice C. Lowen | Influenza virus hemagglutinin polypeptides containing stem domains, vaccines and uses thereof |
| CA2763816A1 (en) * | 2009-04-27 | 2010-11-04 | Novartis Ag | Adjuvanted vaccines for protecting against influenza |
| AU2010254136B2 (en) | 2009-05-26 | 2016-09-29 | Mount Sinai School Of Medicine | Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof |
| WO2011044152A1 (en) * | 2009-10-05 | 2011-04-14 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer | Protection against pandemic and seasonal strains of influenza |
| US9701723B2 (en) | 2010-02-18 | 2017-07-11 | Icahn School Of Medicine At Mount Sinai | Vaccines for use in the prophylaxis and treatment of influenza virus disease |
| CN102939103A (zh) | 2010-03-30 | 2013-02-20 | 西奈山医学院 | 流感病毒疫苗及其应用 |
| JP5884100B2 (ja) * | 2011-08-31 | 2016-03-15 | 公益財団法人東京都医学総合研究所 | 新型インフルエンザウイルス由来ヘマグルチニンタンパク質遺伝子を有するＤＩｓ株由来組換えワクシニアウイルス |
| KR20140068205A (ko) | 2011-09-20 | 2014-06-05 | 마운트 시나이 스쿨 오브 메디슨 | 인플루엔자 바이러스 백신 및 이의 용도 |
| RU2599496C2 (ru) * | 2012-03-06 | 2016-10-10 | Круселл Холланд Б.В. | Улучшенная вакцинация против гриппа |
| JP2016502995A (ja) | 2012-12-17 | 2016-02-01 | ユーロシネ ヴァクシンズ アクチエボラーグ | 鼻腔内予防接種投薬レジメン |
| KR20150104117A (ko) | 2012-12-18 | 2015-09-14 | 이칸 스쿨 오브 메디슨 엣 마운트 시나이 | 인플루엔자 바이러스 백신 및 그의 용도 |
| WO2014159960A1 (en) | 2013-03-14 | 2014-10-02 | Icahn School Of Medicine At Mount Sinai | Antibodies against influenza virus hemagglutinin and uses thereof |
| US10588957B2 (en) | 2013-10-25 | 2020-03-17 | Leukocare Ag | Method for the production of stabile vaccines |
| WO2016100926A1 (en) * | 2014-12-19 | 2016-06-23 | Oregon Health & Science University | Synergistic co-administration of computationally optimized broadly reactive antigens for human and avian h5n1 influenza |
| JP6719388B2 (ja) * | 2014-12-25 | 2020-07-08 | テルモ株式会社 | 皮内投与インフルエンザワクチン組成物 |
| US10736956B2 (en) | 2015-01-23 | 2020-08-11 | Icahn School Of Medicine At Mount Sinai | Influenza virus vaccination regimens |
| AU2016281904B2 (en) | 2015-06-26 | 2022-08-11 | Seqirus UK Limited | Antigenically matched influenza vaccines |
| WO2017218624A1 (en) | 2016-06-15 | 2017-12-21 | Icahn School Of Medicine At Mount Sinai | Influenza virus hemagglutinin proteins and uses thereof |
| CN107151659B (zh) * | 2017-03-01 | 2021-04-02 | 苏州系统医学研究所 | 一种流感病毒株及其应用 |
| WO2018187706A2 (en) | 2017-04-07 | 2018-10-11 | Icahn School Of Medicine At Mount Sinai | Anti-influenza b virus neuraminidase antibodies and uses thereof |
| WO2019086463A1 (en) | 2017-10-30 | 2019-05-09 | Baxalta GmbH | Environmentally compatible detergents for inactivation of lipid-enveloped viruses |
| CN111629751B (zh) * | 2018-01-22 | 2025-02-21 | 美国政府(由卫生和人类服务部的部长所代表) | 广泛保护性灭活流感病毒疫苗 |
| EP3810634A4 (en) | 2018-06-21 | 2022-07-27 | Icahn School of Medicine at Mount Sinai | Mosaic influenza virus hemagglutinin polypeptides and uses thereof |
| EP3959216A4 (en) | 2019-04-24 | 2023-01-11 | Icahn School of Medicine at Mount Sinai | ANTI-INFLUENZA B VIRUS NEURAMINIDASE ANTIBODIES AND USES THEREOF |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1645283A1 (en) * | 2004-10-08 | 2006-04-12 | Chiron Behring GmbH & Co. KG | Combination vaccine |
| TW200700079A (en) * | 2005-03-23 | 2007-01-01 | Glaxosmithkline Biolog Sa | Composition |
| KR101211386B1 (ko) * | 2005-11-04 | 2012-12-13 | 노바티스 백신즈 앤드 다이아그노스틱스 에스.알.엘. | 알루미늄 보조제에 즉석 흡착되는 인플루엔자 백신 |
| US20090304742A1 (en) * | 2005-11-04 | 2009-12-10 | Novartis Vaccines And Diagnostics Srl | Influenza vaccines with reduced amount of emulsion adjuvant |
| WO2007144772A2 (en) * | 2006-06-15 | 2007-12-21 | Novartis Ag | Adjuvant-sparing multi-dose influenza vaccination regimen |
| WO2008032219A2 (en) * | 2006-09-11 | 2008-03-20 | Novartis Ag | Making influenza virus vaccines without using eggs |
| CN101553252A (zh) * | 2006-12-06 | 2009-10-07 | 诺华有限公司 | 包含来自于四株流感病毒的抗原的疫苗 |
| JP5305427B2 (ja) * | 2007-01-11 | 2013-10-02 | 公立大学法人大阪府立大学 | インフルエンザウイルスに対する抗体の産生方法 |
| TWI403518B (zh) * | 2007-01-23 | 2013-08-01 | Academia Sinica | 一種流感疫苗及其使用方法 |
| GB0810305D0 (en) * | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
| US8668904B2 (en) * | 2007-12-06 | 2014-03-11 | Glaxosmithkline Biologicals S.A. | Influenza composition |
| ES2535101T3 (es) * | 2008-03-18 | 2015-05-05 | Novartis Ag | Mejoras en la preparación de antígenos en vacuna de virus de la gripe |
-
2009
- 2009-03-31 GB GBGB0905570.8A patent/GB0905570D0/en not_active Ceased
- 2009-06-12 WO PCT/IB2009/006038 patent/WO2009150532A1/en not_active Ceased
- 2009-06-12 CA CA2727322A patent/CA2727322A1/en not_active Abandoned
- 2009-06-12 CN CN2009801230987A patent/CN102245203A/zh active Pending
- 2009-06-12 JP JP2011513069A patent/JP2011522874A/ja active Pending
- 2009-06-12 KR KR1020117000394A patent/KR20110019417A/ko not_active Ceased
- 2009-06-12 US US12/997,577 patent/US20110200635A1/en not_active Abandoned
- 2009-06-12 EP EP09762060A patent/EP2303321A1/en not_active Withdrawn
- 2009-06-12 AU AU2009259006A patent/AU2009259006A1/en not_active Abandoned
-
2014
- 2014-08-18 US US14/461,852 patent/US20140363468A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011522874A5 (enExample) | ||
| Becker et al. | Influenza vaccines: successes and continuing challenges | |
| Vasou et al. | Targeting pattern recognition receptors (PRR) for vaccine adjuvantation: from synthetic PRR agonists to the potential of defective interfering particles of viruses | |
| Cappellano et al. | Nano-microparticle platforms in developing next-generation vaccines | |
| Kumar et al. | Novel platforms for the development of a universal influenza vaccine | |
| Cargnin Faccin et al. | Pandemic preparedness through vaccine development for avian influenza viruses | |
| Vemula et al. | Vaccine approaches conferring cross-protection against influenza viruses | |
| Sekiya et al. | Selecting and using the appropriate influenza vaccine for each individual | |
| Zhang et al. | Universal influenza vaccines, a dream to be realized soon | |
| Isakova-Sivak et al. | Influenza vaccine: Progress in a vaccine that elicits a broad immune response | |
| JP6185548B2 (ja) | インフルエンザワクチンの製造方法 | |
| Li et al. | Adjuvantation of influenza vaccines to induce cross-protective immunity | |
| Clegg et al. | Clinical vaccine development for H5N1 influenza | |
| Trucchi et al. | Universal influenza virus vaccines: what needs to happen next? | |
| ES2469568T3 (es) | Vacuna contra la gripe | |
| Quan et al. | Progress in the development of virus-like particle vaccines against respiratory viruses | |
| Hatz et al. | A randomized clinical trial to identify the optimal antigen and MF59® adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects | |
| Rudenko et al. | Pandemic preparedness with live attenuated influenza vaccines based on A/Leningrad/134/17/57 master donor virus | |
| Yadav et al. | Assessment of immunogenicity and protective efficacy of ZyCoV-D DNA vaccine candidates in Rhesus macaques against SARS-CoV-2 infection | |
| Hsiung et al. | Vaccine strategies against RNA viruses: current advances and future directions | |
| Chu et al. | Respiratory viruses and virus-like particle vaccine development: how far have we advanced? | |
| Esposito et al. | Preventing influenza in younger children | |
| Tosh et al. | Emerging vaccines for influenza | |
| Deans et al. | Influenza vaccines provide diminished protection but are cost‐saving in older adults | |
| Mokalla et al. | Influenza vaccines: current status, adjuvant strategies, and efficacy |